squamous cell carcinoma of the head and neck
Showing 1 - 25 of 150
Needs and Preferences of Patients With Head-neck Cutaneous SCC
Active, not recruiting
- Cutaneous Squamous Cell Carcinoma
- +10 more
- Regular care with additional administration of a semi-structured interview
-
Maastricht, NetherlandsMaastricht University Medical Center+
Sep 13, 2023
HLA-DR in Cell Cultures Isolated From Primary Squamous Cell
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Cancer
- cell culture
-
Roma, Lazio, ItalyFondazione Policlinico Universitario Gemelli, Irccs
Sep 11, 2023
Squamous Cell Carcinoma of the Head and Neck Trial (Xevinapant, Placebo, cetuximab)
Not yet recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Xevinapant
- +3 more
- (no location specified)
Jul 3, 2023
Breast Cancer, Lung Cancer, Colorectal Cancer Trial in Kobe (e-PRO monitoring)
Enrolling by invitation
- Breast Cancer
- +7 more
- e-PRO monitoring
-
Kobe, Hyogo, JapanKobe University Graduate School
Jun 27, 2023
Squamous Cell Carcinoma of the Head and Neck, Paclitaxel, Carboplatin Trial in Amiens (GCP intratumoral catheter)
Not yet recruiting
- Squamous Cell Carcinoma of the Head and Neck
- +3 more
- intratumoral catheter
-
Amiens, Picardie, FranceCHU Amiens Picardie
Apr 26, 2023
NSCLC, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Trial in Duarte (JANX008)
Recruiting
- Non-Small Cell Lung Cancer
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 29, 2023
Squamous Cell Carcinoma of the Head and Neck Trial in Shanghai (MRG003, Cetuximab injection, Methotrexate Injection)
Not yet recruiting
- Squamous Cell Carcinoma of the Head and Neck
- MRG003
- +2 more
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Feb 21, 2023
Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),
Active, not recruiting
- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Ibrutinib 560mg PO daily (Imbruvica)
- +2 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Jan 11, 2023
Squamous Cell Carcinoma of the Head and Neck Trial in Portland (Intratumoral Ipilimumab)
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Intratumoral Ipilimumab
-
Portland, OregonPortland Providence Medical Center
Jan 8, 2023
Squamous Cell Carcinoma of the Head and Neck Trial in United States (SNS-301, Pembrolizumab)
Terminated
- Squamous Cell Carcinoma of the Head and Neck
-
San Francisco, California
- +9 more
Dec 6, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Ann Arbor (Cisplatin, Carboplatin, IMRT (Intensity-Modulated Radiation
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Cisplatin
- +3 more
-
Ann Arbor, Michigan
- +1 more
Dec 20, 2022
Cancer of Head and Neck, Head Neck Cancer, Tumors, Head and Neck Trial in Boston, Saint Louis, New York (biological, procedure,
Active, not recruiting
- Cancer of Head and Neck
- +5 more
- MK-3475 (neoadjuvant)
- +6 more
-
Boston, Massachusetts
- +2 more
Dec 9, 2022
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, NSCLC Trial in Worldwide (Lifileucel, LN-145, Pembrolizumab)
Recruiting
- Metastatic Melanoma
- +2 more
- Lifileucel
- +5 more
-
La Jolla, California
- +44 more
Dec 16, 2022
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Boston (Interleukin-15
Recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interleukin-15 Superagonist (N-803)
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 2, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Stanford ([18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.)
Completed
- Squamous Cell Carcinoma of the Head and Neck
- [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
-
Stanford, CaliforniaStanford Hospital and Clinics
Dec 1, 2022
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)
Completed
- Melanoma
- +27 more
- XmAb20717
-
Los Angeles, California
- +16 more
Nov 29, 2022
Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma Trial in United Kingdom
Recruiting
- Triple Negative Breast Cancer
- +3 more
- Modi-1/Modi-1v
- +2 more
-
Brighton, Default, United Kingdom
- +13 more
Nov 18, 2022
Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer Trial in France (biological, procedure, other,
Recruiting
- Squamous Cell Carcinoma of the Head and Neck
- +2 more
- Blood sample collection
- +4 more
-
Besançon, France
- +4 more
Nov 17, 2022
NSCLC, Squamous Cell Carcinoma of the Head and Neck Trial in Lexington (Immune checkpoint inhibitor, Radiation Therapy)
Recruiting
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Immune checkpoint inhibitor
- Radiation Therapy
-
Lexington, KentuckyUniversity of Kentucky Markey Cancer Center
Nov 10, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Worldwide (Monalizumab, Cetuximab)
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
-
Tucson, Arizona
- +126 more
Oct 21, 2022
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma Trial in United States
Active, not recruiting
- Non-small-cell Lung Cancer
- +5 more
- PF-07209960
-
Duarte, California
- +11 more
Oct 10, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in United States (Dalantercept)
Completed
- Squamous Cell Carcinoma of the Head and Neck
- Dalantercept
-
Aurora, Colorado
- +7 more
Sep 13, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Worldwide (Nivolumab, Cetuximab, Methotrexate)
Completed
- Squamous Cell Carcinoma of the Head and Neck
- Nivolumab
- +3 more
-
Stanford, California
- +63 more
Sep 6, 2022